PETALING JAYA: Amid the challenging economic conditions compounded by the Covid-19 outbreak, Duopharma Biotech Bhd
expects its revenue for this year to be spurred by the expansion of its product range.
The associate of Permodalan Nasional Bhd (PNB) and one of the leading players in the pharmaceutical space said it is also on track to achieve its production target this year.
Already a subscriber? Log in
Get 20% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
